Cargando…
Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients
BACKGROUND: In this study, we investigated the ability of prostate-specific antigen (PSA) 12 months after (nPSA12) external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT) to predict biochemical recurrence-free survival (BRFS), overall survival (OS), and prostate cancer-spe...
Autores principales: | Cetin, Ilknur Alsan, Akay, Sıtkı Utku, Sengoz, Meric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664688/ https://www.ncbi.nlm.nih.gov/pubmed/36376849 http://dx.doi.org/10.1186/s12894-022-01125-1 |
Ejemplares similares
-
Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer
por: Hong, Seok Young, et al.
Publicado: (2012) -
Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2021) -
Correction: Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2022) -
The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2021) -
The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients
por: Sasaki, Takeshi, et al.
Publicado: (2018)